ALK and neoplasm: All around the world, there are many ongoing clinical trials testing different combinations with or without ALK-Is using several drug classes (chemotherapy, immune checkpoint inhibitors, antiangiogenic drugs, and even novel immune modulators), but we think little or no further improvement will occur, since they are aimed at an unselected patient population and are trying, in case of immunotherapies, to transform a cold to a hot tumor, such as ALK+ disease [112].